Eulav Asset Management Exelixis, Inc. Transaction History

Eulav Asset Management

$4.06 Billion
Q1 2025

A detailed history of Eulav Asset Management transactions in Exelixis, Inc. stock. As of the latest transaction made, Eulav Asset Management holds 530,000 shares of EXEL stock, worth $21.6 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares

530,000

Previous 480,000 10.42%

Holding current value

$21.6 Million

Previous $16 Million 22.42%

% of portfolio

0.48%

Previous 0.38%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 29, 2025	BUY	$32.38 - $39.16 $1.62 Million - $1.96 Million	50,000 Added 10.42%	530,000 $19.6 Million
Q4 2024 Jan 28, 2025	SELL	$25.39 - $36.46 $507,800 - $729,200	-20,000 Reduced 4.0%	480,000 $16 Million
Q3 2024 Nov 08, 2024	SELL	$21.96 - $27.6 $988,200 - $1.24 Million	-45,000 Reduced 8.26%	500,000 $13 Million
Q2 2024 Aug 13, 2024	SELL	$20.34 - $23.73 $1.32 Million - $1.54 Million	-65,000 Reduced 10.66%	545,000 $12.2 Million
Q1 2024 May 30, 2024	SELL	$20.17 - $23.93 $806,800 - $957,200	-40,000 Reduced 6.15%	610,000 $14.5 Million
Q3 2023 Nov 13, 2023	SELL	$19.04 - $22.74 $380,800 - $454,799	-20,000 Reduced 2.99%	650,000 $14.2 Million
Q2 2023 Aug 09, 2023	SELL	$18.17 - $20.48 $1.27 Million - $1.43 Million	-70,000 Reduced 9.46%	670,000 $12.8 Million
Q1 2023 Apr 27, 2023	SELL	$16.3 - $19.41 $2.93 Million - $3.49 Million	-180,000 Reduced 19.57%	740,000 $14.4 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $1.35 Million - $1.57 Million	90,000 Added 10.84%	920,000 $14.8 Million
Q3 2022 Nov 03, 2022	SELL	$15.68 - $22.27 $1.41 Million - $2 Million	-90,000 Reduced 9.78%	830,000 $13 Million
Q2 2022 Jul 22, 2022	SELL	$17.44 - $23.16 $8.72 Million - $11.6 Million	-500,000 Reduced 35.21%	920,000 $19.2 Million
Q1 2022 May 10, 2022	SELL	$17.03 - $22.67 $8.52 Million - $11.3 Million	-500,000 Reduced 26.04%	1,420,000 $32.2 Million
Q4 2021 Feb 11, 2022	SELL	$15.84 - $21.88 $475,200 - $656,400	-30,000 Reduced 1.54%	1,920,000 $35.1 Million
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $1.3 Million - $1.69 Million	-80,000 Reduced 3.94%	1,950,000 $41.2 Million
Q2 2021 Aug 06, 2021	SELL	$17.95 - $25.56 $7.72 Million - $11 Million	-430,000 Reduced 17.48%	2,030,000 $37 Million
Q1 2021 Apr 30, 2021	BUY	$20.53 - $25.22 $11.7 Million - $14.4 Million	570,000 Added 30.16%	2,460,000 $55.6 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $9.38 Million - $12.6 Million	510,000 Added 36.96%	1,890,000 $37.9 Million
Q3 2020 Nov 05, 2020	BUY	$20.67 - $26.94 $3.93 Million - $5.12 Million	190,000 Added 15.97%	1,380,000 $33.7 Million
Q2 2020 Aug 11, 2020	BUY	$16.46 - $27.42 $329,200 - $548,400	20,000 Added 1.71%	1,190,000 $28.3 Million
Q1 2020 Apr 27, 2020	BUY	$14.46 - $21.8 $2.39 Million - $3.6 Million	165,000 Added 16.42%	1,170,000 $20.1 Million
Q4 2019 Feb 13, 2020	SELL	$15.15 - $18.89 $1.82 Million - $2.27 Million	-120,000 Reduced 10.67%	1,005,000 $17.7 Million
Q3 2019 Nov 12, 2019	SELL	$17.68 - $22.65 $884,000 - $1.13 Million	-50,000 Reduced 4.26%	1,125,000 $19.9 Million
Q2 2019 Aug 05, 2019	BUY	$18.93 - $24.75 $3.98 Million - $5.2 Million	210,000 Added 21.76%	1,175,000 $25.1 Million
Q1 2019 May 13, 2019	SELL	$19.6 - $24.76 $686,000 - $866,600	-35,000 Reduced 3.5%	965,000 $23.4 Million
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $682,500 - $1.09 Million	50,000 Added 5.26%	1,000,000 $19.7 Million
Q3 2018 Oct 26, 2018	BUY	$15.87 - $22.4 $3.65 Million - $5.15 Million	230,000 Added 31.94%	950,000 $16.8 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $5.75 Million - $6.96 Million	310,000 Added 75.61%	720,000 $15.5 Million
Q1 2018 May 09, 2018	BUY	$22.15 - $31.89 $9.08 Million - $13.1 Million	410,000 New	410,000 $9.08 Million

Others Institutions Holding EXEL

# of Institutions

613

Shares Held

257M

Call Options Held

1.57M

Put Options Held

730K

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $13.1B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Eulav Asset Management with notifications on news.

Account

Eulav Asset Management Exelixis, Inc. Transaction History